Now showing items 1-1 of 1

  • A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway 

    Perreault, Sébastien; Larouche, Valérie; Tabor, Uri; Hawkin, Cynthia; Lippé, Sarah; Ellezam, Benjamin; Décarie, Jean-Claude; Théoret, Yves; Métras, Marie-Élaine; Sultan, Serge; Cantin, Édith; Routhier, Marie-Ève; Caru, Maxime; Legault, Geneviève; Bouffet, Éric; Lafay-Cousin, Lucie; Hukin, Juliette; Erker, Craig; Jabado, Nada (BMC, 2019-12-27)
    Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway ...